Developer · Switzerland
Synendos Therapeutics AG
Private clinical-stage neuroscience company based in Basel, Switzerland, incorporated in April 2019 as a spin-out of the University of Bern. It develops Selective Endocannabinoid Reuptake Inhibitors (SERIs), a new class of endocannabinoid-system modulators, for anxiety, mood and stress-related disorders. Lead asset SYT-510 is in Phase 2 in generalized anxiety disorder.
Pipeline (1)
- Generalized anxiety disorderPhase 2Recruiting
Catalysts · 1 upcoming · 1 reported
- Early 2027Anticipated
SYT-510forGeneralized anxiety disorderTopline data
Preliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027.
Recently reported
- 2025-09-24met
SYT-510forGeneralized anxiety disorderTopline data
Phase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.
Recent activity
- Apr 22, 2026Phase changeSYT-510·Generalized anxiety disorderPhase 2Phase 2a NCT07478744 started (actual start date per ClinicalTrials.gov); Synendos publicly announced the start of dosing on 2026-05-20.source ↗
- Sep 24, 2025ReadoutSYT-510·Generalized anxiety disordermetPhase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.source ↗
- Jan 18, 2024Phase changeSYT-510·Generalized anxiety disorderPhase 1Synendos announced EMA authorisation to begin the Phase 1 first-in-human, randomized, double-blind, placebo-controlled single-ascending-dose study of SYT-510 in healthy adults. The SAD study is not registered on ClinicalTrials.gov and its first-dosing date is not disclosed, so this authorisation date is a lower bound for entry into Phase 1.source ↗
Trials recruiting · 1 recruiting of 2 sponsored
- Phase 2SYT-510
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
Competitive landscape
Other companies developing against Synendos Therapeutics AG's targets or indications.
- Definium Therapeutics, Inc.1 compoundGeneralized anxiety disorder
- F. Hoffmann-La Roche Ltd1 compoundGeneralized anxiety disorder
- Gedeon Richter Plc.1 compoundGeneralized anxiety disorder
- Helus Pharma1 compoundGeneralized anxiety disorder
- Intra-Cellular Therapies, Inc.1 compoundGeneralized anxiety disorder
- Otsuka Pharmaceutical Co., Ltd.1 compoundGeneralized anxiety disorder
- Protagenic Therapeutics, Inc.1 compoundGeneralized anxiety disorder
- Reunion Neuroscience Inc.1 compoundGeneralized anxiety disorder
- Seaport Therapeutics1 compoundGeneralized anxiety disorder